70 related articles for article (PubMed ID: 7742601)
1. [Immunoradionuclide localization of human neuroblastoma xenografted in nude mice using anti-GD2 labelled with I125].
Perdereau B; Barbaroux C; Michon J; Fridman WH; Rosin N; Validire P; Zucker JM; Manil L
Bull Cancer; 1994 Jul; 81(7):593-8. PubMed ID: 7742601
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
3. Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma.
Cheung NK; Neely JE; Landmeier B; Nelson D; Miraldi F
J Nucl Med; 1987 Oct; 28(10):1577-83. PubMed ID: 3655911
[TBL] [Abstract][Full Text] [Related]
4. In vivo targeting of human neuroblastoma xenograft by anti-GD2/anti-Fc gamma RI (CD64) bispecific antibody.
Michon J; Perdereau B; Brixy F; Moutel S; Fridman WH; Teillaud JL
Eur J Cancer; 1995; 31A(4):631-6. PubMed ID: 7576984
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunodetection of neuroblastoma cells with I-131-radiolabelled antibodies.
Voigt A; Berndt A; Lauterbach H; Carlsohn H; Hüller M; Stiller KJ; Gottschild D; Zintl F
Cancer Biother Radiopharm; 1997 Jun; 12(3):187-94. PubMed ID: 10851465
[TBL] [Abstract][Full Text] [Related]
6. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice.
Cheung NK; Landmeier B; Neely J; Nelson AD; Abramowsky C; Ellery S; Adams RB; Miraldi F
J Natl Cancer Inst; 1986 Sep; 77(3):739-45. PubMed ID: 3091900
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities.
Yeh SD; Larson SM; Burch L; Kushner BH; Laquaglia M; Finn R; Cheung NK
J Nucl Med; 1991 May; 32(5):769-76. PubMed ID: 1902508
[TBL] [Abstract][Full Text] [Related]
8. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
[TBL] [Abstract][Full Text] [Related]
9. New anti-GD2 monoclonal antibodies produced from gamma-interferon-treated neuroblastoma cells.
Gross N; Beck D; Portoukalian J; Favre S; Carrel S
Int J Cancer; 1989 Apr; 43(4):665-71. PubMed ID: 2467885
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunolocalization of neuroblastoma xenografts with chimeric antibody chCE7.
Novak-Hofer I; Amstutz HP; Haldemann A; Blaser K; Morgenthaler JJ; Bläuenstein P; Schubiger PA
J Nucl Med; 1992 Feb; 33(2):231-6. PubMed ID: 1732444
[TBL] [Abstract][Full Text] [Related]
11. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
12. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.
Kusano A; Ohta S; Shitara K; Hanai N
Anticancer Res; 1993; 13(6A):2207-12. PubMed ID: 8297135
[TBL] [Abstract][Full Text] [Related]
13. Strong uptake of 111In-pentetreotide by an MIBG-negative, xenografted neuroblastoma.
Manil L; Perdereau B; Barbaroux C; Brixy F
Int J Cancer; 1994 Apr; 57(2):245-6. PubMed ID: 7908895
[TBL] [Abstract][Full Text] [Related]
14. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma.
Heiner JP; Miraldi F; Kallick S; Makley J; Neely J; Smith-Mensah WH; Cheung NK
Cancer Res; 1987 Oct; 47(20):5377-81. PubMed ID: 3115567
[TBL] [Abstract][Full Text] [Related]
15. Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model.
Ugur O; Scott AM; Kostakoglu L; Hui TE; Masterson ME; Febo R; Sgouros G; Rosa E; Mehta BM; Fisher DR
Nucl Med Biol; 1995 Jan; 22(1):87-93. PubMed ID: 7735175
[TBL] [Abstract][Full Text] [Related]
16. Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2).
Moutel S; Birkle S; Laurence V; Michon J; Fridman WH; Aubry J; Teillaud JL
Hybridoma; 1997 Aug; 16(4):335-46. PubMed ID: 9309424
[TBL] [Abstract][Full Text] [Related]
17. Treatment of high-risk neuroblastoma with anti-GD2 antibodies.
Castel V; Segura V; Cañete A
Clin Transl Oncol; 2010 Dec; 12(12):788-93. PubMed ID: 21156409
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma.
Handgretinger R; Anderson K; Lang P; Dopfer R; Klingebiel T; Schrappe M; Reuland P; Gillies SD; Reisfeld RA; Neithammer D
Eur J Cancer; 1995; 31A(2):261-7. PubMed ID: 7718335
[TBL] [Abstract][Full Text] [Related]
19. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
20. Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.
Müller J; Reichel R; Vogt S; Müller SP; Sauerwein W; Brandau W; Eggert A; Schramm A
PLoS One; 2016; 11(10):e0163648. PubMed ID: 27716771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
